Heavily Pretreated RRMM: Patient Assessment & Treatment Selection

Video

test 2

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
Data from the phase 1/2 RAINFOL-01 trial support the agency’s regulatory decision on rinatabart sesutecan in advanced endometrial cancer.

Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer

Russ Conroy
August 26th 2025
Article
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 26th 2025
Podcast
Developers launched a clinical laboratory-developed test version of Haystack MRD in late 2024 and are further expanding access for oncologists.

Haystack MRD Test Earns FDA Breakthrough Device Designation in Stage II CRC

Roman Fabbricatore
August 26th 2025
Article
Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 26th 2025
Podcast
Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera

Ariana Pelosci
August 26th 2025
Article
Developers will now initiate the phase 3 MarsLight-11 trial of IBI363 among patients with immunotherapy-resistant squamous non–small cell lung cancer.

FDA Clears IND for IBI363 in Squamous Non–Small Cell Lung Cancer

Russ Conroy
August 26th 2025
Article